Description: Genflow Biosciences plc operates as a biotechnology company that focuses on developing therapies to counteract the effects of aging and diseases associated with advanced age. Its lead compound is GF-1002, a suspension of an adeno-associated viral vector-based gene therapy for intravenous infusion. The company is also developing GF-3001, a topical delivery of SIRT6 to the skin; and GF-4001, a non-human pipeline anti-aging for veterinary use. The company was incorporated in 2021 and is headquartered in London, the United Kingdom.
Home Page: genflowbio.com
GENF Technical Analysis
15 Ingestre Place
London,
W1F 0DU
United Kingdom
Phone:
44 32 4774 95881
Officers
| Name | Title |
|---|---|
| Dr. Eric Jean Leire M.D., MBA | Founder, CEO & Exec. Director |
| Dr. Cedric Szpirer | Head of CMC |
Exchange: LSE
Country: UK
Currency: Pence sterling (p)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 3.1119 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 2 |